HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Combined infection with HTLV-1 and Strongyloides stercoralis].

Abstract
Infection of carriers of strongyloides by the human oncogenic retrovirus HTLV-1 significantly augments the number of larval parasites in the stools and impairs the action of anti-helminthic agents, resulting in an increase in immediate and longer term failure of therapy. The proliferation of cytokine type 1 secreting lymphocytes, the preferred target for viral infection, shifts the Th1/Th2 balance in favour of a Th1 response with a consequent increase in the production of gamma interferon (INF-γ). In addition to other effects, this causes a decrease in the secretion of cytokines IL-4, IL-5 and IL-13, which results in substantial reduction in total and specific IgE; failure of activation of eosinophils or stagnation in or reduction of their numbers; and an increased risk of development of a severe form of strongyloidiasis. This risk is clearly correlated with the level of anti-HTLV-1 antibodies and the amplitude of the proviral load of peripheral lymphocytes. The polyclonal expansion of infected CD4 cells might be partly due to the activation of the IL-2/IL-2R system by parasite antigens together with the action of the virus type 1 Tax protein. The fact that adult T cell leukaemia arises significantly earlier and more often in individuals with combined infection is an argument in favour of the parasite's role as a leukaemogenic co-factor. In practice it is, therefore, appropriate to initiate all available measures to eliminate parasites from co-infected hosts although this does present difficulties, and one should not reject the possibility of a diagnosis of strongyloidiasis in the absence of hypereosinophilia. In all cases of chronic strongyloidiasis without hypereosinophilia, co-infection with HTLV-1 should be looked for routinely. The same applies to carriers of strongyloides with repeated treatment failures. Finally, corticosteroids and immunosuppressants should be used only with care in HTLV-1-positive patients who seem not to be co-infected, even if they have received precautionary therapy.
AuthorsJ-F Pays
JournalBulletin de la Societe de pathologie exotique (1990) (Bull Soc Pathol Exot) Vol. 104 Issue 3 Pg. 188-99 (Aug 2011) ISSN: 0037-9085 [Print] France
Vernacular TitleCo-infections HTLV-1-Strongyloides stercoralis.
PMID21800110 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Anthelmintics
  • Immunoglobulin E
Topics
  • Animals
  • Anthelmintics (therapeutic use)
  • Cocarcinogenesis
  • Comorbidity
  • Disease Progression
  • Drug Resistance
  • Eosinophils (physiology)
  • HTLV-I Infections (complications, epidemiology, immunology)
  • Host-Parasite Interactions (immunology)
  • Humans
  • Immunoglobulin E (immunology)
  • Larva
  • Leukemia-Lymphoma, Adult T-Cell (etiology)
  • Life Cycle Stages
  • Models, Biological
  • Opportunistic Infections (parasitology)
  • Prevalence
  • Strongyloides stercoralis (growth & development, physiology)
  • Strongyloidiasis (complications, drug therapy, epidemiology, immunology)
  • Terminology as Topic
  • Th1-Th2 Balance

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: